The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Fennec Pharmaceuticals Inc (NASDAQ: FENC) closed at $7.89 down -0.75% from its previous closing price of $7.95. In other words, the price has decreased by -$0.75 from its previous closing price. On the day, 0.25 million shares were traded. FENC stock price reached its highest trading level at $8.0 during the session, while it also had its lowest trading level at $7.72.
Ratios:
For a deeper understanding of Fennec Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.44 and its Current Ratio is at 4.69.
Upgrades & Downgrades
In the most recent recommendation for the company, Cantor Fitzgerald on November 22, 2022, Upgraded its rating to Overweight and sets its target price to $12 from $9 previously.
On September 07, 2022, CapitalOne started tracking the stock assigning a Overweight rating and target price of $11.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 18 ’25 when Southpoint Capital Advisors LP sold 19,341 shares for $8.79 per share. The transaction valued at 170,048 led to the insider holds 3,744,741 shares of the business.
Southpoint Capital Advisors LP sold 160,100 shares of FENC for $1,280,432 on Nov 14 ’25. The 10% Owner now owns 3,850,000 shares after completing the transaction at $8.00 per share. On Nov 17 ’25, another insider, Southpoint Capital Advisors LP, who serves as the 10% Owner of the company, sold 85,918 shares for $8.79 each. As a result, the insider received 755,193 and left with 3,764,082 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FENC now has a Market Capitalization of 269471072 and an Enterprise Value of 219271776. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.72. Its current Enterprise Value per Revenue stands at 5.653 whereas that against EBITDA is -50.675.
Stock Price History:
The Beta on a monthly basis for FENC is 0.76, which has changed by 0.31188118 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, FENC has reached a high of $9.92, while it has fallen to a 52-week low of $4.68. The 50-Day Moving Average of the stock is -7.84%, while the 200-Day Moving Average is calculated to be 2.17%.
Shares Statistics:
For the past three months, FENC has traded an average of 104.13K shares per day and 272820 over the past ten days. A total of 28.06M shares are outstanding, with a floating share count of 20.84M. Insiders hold about 25.87% of the company’s shares, while institutions hold 60.99% stake in the company. Shares short for FENC as of 1763078400 were 1073787 with a Short Ratio of 10.31, compared to 1760486400 on 1308525. Therefore, it implies a Short% of Shares Outstanding of 1073787 and a Short% of Float of 5.48.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Fennec Pharmaceuticals Inc (FENC) in the stock market.The consensus estimate for the next quarter is $0.19, with high estimates of $0.32 and low estimates of $0.07.
Analysts are recommending an EPS of between -$0.12 and -$0.12 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is $0.79, with 2.0 analysts recommending between $0.92 and $0.65.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $14.21M this quarter.It ranges from a high estimate of $14.58M to a low estimate of $13.86M. As of. The current estimate, Fennec Pharmaceuticals Inc’s year-ago sales were $7.92MFor the next quarter, 4 analysts are estimating revenue of $17.48M. There is a high estimate of $23.8M for the next quarter, whereas the lowest estimate is $13.93M.
A total of 3 analysts have provided revenue estimates for FENC’s current fiscal year. The highest revenue estimate was $45.44M, while the lowest revenue estimate was $44.73M, resulting in an average revenue estimate of $45.02M. In the same quarter a year ago, actual revenue was $47.54MBased on 5 analysts’ estimates, the company’s revenue will be $76.69M in the next fiscal year. The high estimate is $87.02M and the low estimate is $60.57M.
